Table 7.

Response by CTCL subtype

CTCL subtypeORRCRPR
All evaluable patients (N = 33)a20 (61%)4 (12%)16 (48%)
MF (n = 19)12 (63%)2 (11%)10 (53%)
Transformed MF (n = 10)5 (50%)1 (10%)4 (40%)
S├ęzary syndrome (n = 3)2 (67%)0 (0)2 (67%)
ALCL (n = 1)1 (100%)1 (100%)0 (0)
Stage of MF respondersIIB, IVA2(2)t-IA;IB(3);IIa (3); IIb(7); & III;IVA1;IVB (1)
  • Abbreviations: MF, mycosis fungoides; t, transformed.

  • aIncluded all patients who received at least 1 dose of pralatrexate or bexarotene and had a baseline response evaluation.